- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05838911
Does Neuromuscular Electrical Stimulation Benefit the Functional Ability of Elderly Patients With Chronic Obstructive Lung Disease (NEMS for COPD)
Background: Patients with COPD often experience skeletal muscle dysfunction. For those who are unable or unwilling to undertake physical training, neuromuscular electrical stimulation (NMES) may provide an alternative method of exercise training.
Objective: To investigate the effects of adding neuromuscular electrical stimulation of gluteus maximus, quadriceps and calf muscles to chest physiotherapy, compared to chest physiotherapy alone, on muscles strength (gluteus max., quadriceps, calf muscles), femoral blood flow physical and pulmonary function in severe COPD Patients.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Qinā, Egypt
- Department of P.T for internal medicine, Faculty of Physical Therapy, South valley university, Qena, Egypt
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A diagnosis of COPD with FEV1/FVC <50% predicted as per the GOLD guidelines.
- Self-reported dyspnea and/or arm fatigue during at least one activity of daily living that required arm exercise.
- Dyspnea and/or physical activity fatigue were self-reported by the Borg Scale.
- Before entering in the study, all patients had their pulmonary function optimized with long-acting bronchodilators and corticosteroids.
Exclusion Criteria:
• Patients with unstable angina pectoris.
- Progressive ventricular dysrhythmia.
- Intermittent claudication.
- Implanted cardiac pacemakers.
- Uncontrolled diabetes mellitus.
- Peripheral vascular disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Control Group
The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks.
|
The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks
Other Names:
|
|
Experimental: Study Group
The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation (NMES) of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for three consecutive weeks.
|
The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for three consecutive weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscle strength measurement
Time Frame: change from baseline to 3 weeks after intervention and 3 days as a follow-up
|
To determine the maximal muscle strength the Lafayette manual muscle test system (USER MANUAL) (MMT) Model 01163, White Plains, New York (10602) of gluteus maximus, quadriceps and calf muscles will be measured on right lower limb.
|
change from baseline to 3 weeks after intervention and 3 days as a follow-up
|
|
Pulmonary function test
Time Frame: change from baseline to 3 weeks after intervention and 3 days as a follow-up
|
Pulmonary capacity and respiratory muscle functions will be assessed using the CPFS/D USB™ 187 Spirometer (Medical Graphics-MGC, St. Paul, MN, USA) with airflow being measured by a 188 calibrated Pitot tube (PreVent, Pneumotach).
The participant completed at least three acceptable maximal forced and slow expiratory maneuvers after 15 min the inhalation of 400 mg of salbutamol 190 via a metered-dose inhaler.
Forced vital capacity (FVC, L), forced expiratory volume in one second (FEV1, L), FEV1/ FVC, and inspiratory capacity (IC) will be measured according to American Thoracic Society standards
|
change from baseline to 3 weeks after intervention and 3 days as a follow-up
|
|
Six-minute walking test (Physical function assessment
Time Frame: change from baseline to 3 weeks after intervention and 3 days as a follow-up
|
The six-minute walking distance (6MWD) was measured according to a standardized protocol.
|
change from baseline to 3 weeks after intervention and 3 days as a follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood flow velocimetry measurement
Time Frame: change from baseline to 3 weeks after intervention and 3 days as a follow-up
|
To evaluate changes in peripheral perfusion.
The standard pulsed-wave Doppler velocimetry of the right femoral artery was performed using sonos 2000 echograph (Philips Envisor )
|
change from baseline to 3 weeks after intervention and 3 days as a follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Ibrahim I. I Abu zaid, PhD, Department of P.T for internal medicine, Faculty of Physical Therapy, South valley university, Qena, Egypt
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BeniSuefU_1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.